Skip to main content
x

BioNTech enters the TROP2 space

BioNTech has followed an April deal with DualityBio with the acquisition of ex-China rights to the Chinese group's TROP2-targeted antibody-drug conjugate DB-1305. The molecule is being evaluated in a first-in-human trial in advanced solid tumours including NSCLC, SCLC, HR+/HER2- breast cancer and TNBC. The agreement expands on the original deal from April 2023 where BioNTech licensed ex-China rights to DB-1303 (anti-HER2 ADC) and DB-1311 (anti-B7-H3). DualityBio received $170 million up front and is eligible to receive up to $1.5 billion in milestone payments for both assets. Last month BeiGene entered into a $1.3 billion deal with DualityBio for the exclusive option to a preclinical ADC program for select solid tumours.

 

Anti-TROP-2 projects in clinical development

ProjectCompanyClinical enrolment
TrodelvyGilead82 trials, 15,245 patients
Datopotamab deruxtecanDaiichi Sankyo/AstraZeneca18 trials, 8,537 patients
Sacituzumab tirumotecanKelun/Merck & Co11 trials, 1,962 patients
MHB036CMinghui Pharmaceutical2 trials, 400 patients
BIO-106BiOneCure1 trial, 332 patients
SHR-A1921Jiangsu Hengrui Medicine4 trials, 311 patients
LCB84LegoChem1 trial, 300 patients
DB-1305DualityBio/BioNTech1 trial, 235 patients
STI-3258Sorrento2 trials, 207 patients
BAT8008Bio-Thera2 trials, 182 patients
IBI130Innovent1 trial, 182 patients
FZ-AD004Shanghai Fudan-Zhangjiang1 trial, 121 patients
BL-M02D1SystImmune3 trials, 112 patients
FDA018Shanghai Fudan-Zhangjiang1 trial, 78 patients
MT-302*Myeloid Therapeutics1 trial, 48 patients
JS108Shanghai Junshi Bioscience1 trial, 25 patients

Note: *mRNA encoding in vivo Car against TROP2, delivered in LNP; all others are ADCs. Source: OncologyPipeline.

Tags

Molecular Drug Targets